[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100273204":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":48,"collaborators":29,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":29,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":29,"studyType":65,"phases":66,"briefSummary":69,"conditions":70,"keywords":29,"overallStatus":34,"whyStopped":29,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"R-IDARAM plus intrathecal chemotherapy","EXPERIMENTAL","Patients will be treated with systemic R-IDARAM plus intrathecal immunochemotherapy",[13],"Drug: R-IDARAM plus intrathecal chemotherapy",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","R-IDARAM comprised of rituximab 375 mg\u002Fm2 (day 1), idarubicin 10 mg\u002Fm2(day 2); dexamethasone 100 mg\u002Fm2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g\u002Fm2 (1 h. infusion in day 2); methotrexate 1.5 g\u002Fm2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 20mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.",[9],[20],"R-IDARAM plus intrathecal immuochemotherapy",[22],{"name":23,"affiliation":5,"role":24},"Liren Qian, M.D.","STUDY_CHAIR",[26],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","+861066957676",null,"qlr2007@126.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Navy General Hospital","RECRUITING","Beijing","Beijing Municipality","100048","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Liren Qian","Doctor","100273204","phase-2-therapeutic-effects-of-r-idaram-and-intrathecal-immunochemotherapy-on-elderly-patients-with-pcnsl-100273204",false,"NCT02836158","Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL","Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With Primary CNS Lymphoma","Inclusion Criteria:\n\n* Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).\n\nExclusion Criteria:\n\n* Involved sites other than the brain, meninges, CSF, or the eyes.\n* Age less than 18 years or greater than 75 years.\n* Inadequate bone marrow capacity (defined as neutrophils\\\u003C1.5 ×10\\^9\u002FL, platelets \\\u003C100 ×10\\^9\u002FL, and hemoglobin level\\\u003C 8 g\u002FdL).\n* Known cause of immunosuppression (ie, HIV type I infection).\n* Any previous malignancy.\n* Creatinine clearance below 60 mL\u002Fmin.\n* Heart insufficiency (NYHA IIIB or IV).\n* Uncontrolled infection.\n* Noncompensated active pulmonary or liver disease.\n* Previously treated for PCNSL, except by corticosteroids.","ALL","60 Years","75 Years",{"count":63,"type":64},100,"ESTIMATED","INTERVENTIONAL",[67,68],"PHASE2","PHASE3","This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (PCNSL).",[71],"Primary Central Nervous System Lymphoma","2020-09-08",{"date":74,"type":75},"2020-09-09","ACTUAL",{"date":77,"type":29},"2010-09",{"date":79,"type":64},"2030-12",{"name":5,"class":6},1]